Updates

February 25, 2021August 24, 2022
FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer

Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. This designation helps speed ... Read more
February 23, 2021February 23, 2021
She ROCKS Raises $100K to Support Early Work Into Stem Cell Therapy

She ROCKS, an organization working for earlier diagnosis and better treatments for ovarian cancer, raised $100,000 through recent virtual luncheon fundraisers to support ongoing research ... Read more
February 18, 2021February 18, 2021
Progesterone May Help Drive Spread of Ovarian Cancer, Preclinical Study Shows

The hormone progesterone helps to drive the development of metastatic ovarian cancer, and blocking progesterone signaling may be a useful strategy for preventing the cancer, ... Read more
February 16, 2021February 16, 2021
InVivo Analytics Granted $1.7M to Advance Preclinical 3D Imaging

InVivo Analytics has received $1.7 million to develop and commercialize its next-generation fluorescence imaging device, called InVivoFLUOR, for 3D monitoring of immune cell migration in ... Read more
February 11, 2021February 11, 2021
ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors

ENB Therapeutics’ lead novel anti-cancer therapy, ENB-003, was found to be safe and showed promising anti-tumor activity, when given in combination with Keytruda (pembrolizumab), to ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

February 9, 2018

Prexasertib Shrinks Ovarian Cancer Tumors in a Third of Phase 2 Trial Participants

News

The DNA repair inhibitor prexasertib shrank the tumors of a third of the ovarian cancer patients treated with it in a Phase 2 clinical trial, preliminary results show. Its developer, Eli Lilly, said the participants had recurring cancer that failed to ... Read more

Updates

FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer

She ROCKS Raises $100K to Support Early Work Into Stem Cell Therapy

Progesterone May Help Drive Spread of Ovarian Cancer, Preclinical Study Shows

InVivo Analytics Granted $1.7M to Advance Preclinical 3D Imaging

ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors

€15M EU Project Seeks to Improve Personalized Medicine Options

Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer

Blocking Glutamine Metabolism May Help Combat OCCC Tumors

BioVaxys Advances Plans to Bring Vaccine to Clinic

Combining Imaging Methods May Reduce Need for Tumor Biopsies

Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer

Subscribe to our mailing list

UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial

GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

$34M Funding Helps Speed Up New Class of Cancer Diagnostics

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial

STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer

$3.2M NIH Grant Supports Development of New Approach to Target ‘Invisible’ Residual Tumors

Anixa Enters License Agreement With Cleveland Clinic for Ovarian Cancer Vaccine

Phase 2 Trial Begins Testing VS-6766, Defactinib Combo in Low-grade Serous Ovarian Cancer

CRISPR-Cas9 in Lipid Nanoparticles Found to Safely Treat Ovarian Cancer in Mice

Assisted Reproductive Technology Does Not Raise Risk of Ovarian Cancer, Study Indicates

New $100M Program Aims to Improve Diversity in Clinical Trials

ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression

Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women

ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China

CA125 Blood Test Useful in Diagnosing Ovarian Cancer in Routine Setting

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer

Prexasertib Shrinks Ovarian Cancer Tumors in a Third of Phase 2 Trial Participants